Eli Lilly announced on Thursday that its next-generation weight loss drug, retatrutide, has successfully completed a crucial late-stage Phase 3 trial for patients battling obesity. The trial demonstrated unprecedented levels of weight loss across various dosages, propelling Lilly closer to seeking regulatory approval for the weekly injectable medication. Retatrutide distinguishes itself from current weight loss treatments through its novel mechanism of action.
In the pivotal trial, the highest dose of retatrutide facilitated an average weight loss of 28.3%, translating to approximately 70.3 pounds, over an 80-week treatment period. This figure is in sharp contrast to the mere 2.2% weight loss observed in the placebo group among patients who adhered to the prescribed regimen. Furthermore, Lilly reported that approximately 45% of the 2,500 participants in the Phase 3 trial achieved a remarkable weight loss of 30% or more. This level of efficacy has historically been associated primarily with bariatric surgery.
An extension of the study specifically focused on participants with a Body Mass Index (BMI) of 35 or higher, a critical threshold indicating a significantly elevated risk for cardiovascular complications and the onset of diabetes. Within this high-risk subgroup, the highest dose of retatrutide led to an average weight loss of 30.3% over a 104-week period. These findings strongly underscore the drug's potent capacity for substantial weight reduction, particularly in individuals facing greater health challenges.
Around 65% of individuals receiving the highest dose of retatrutide also achieved a BMI below 30 by the 80-week mark, falling outside the clinical definition of obesity. This outcome further highlights the drug's profound impact on body composition and metabolic health.
While the drug exhibited a higher incidence of gastrointestinal side effects, including nausea and diarrhea, particularly at the highest dosage, these adverse events were generally consistent with observations from a prior Phase 3 trial involving retatrutide for obesity and knee arthritis. Some analysts have suggested that these side effects may, in fact, serve as indicators of the drug's rapid and substantial impact on weight loss. A lower dose of retatrutide tested in the current study was associated with fewer treatment discontinuations due to adverse effects.
Dan Skovronsky, Lilly's chief scientific and product officer, described the 30% weight loss as an "incredible number to see," emphasizing that such results have previously been attainable only through bariatric surgery. "We haven't seen that level of weight loss before with these kinds of medicines," Skovronsky stated in an interview with CNBC. He further noted that for some patients, 30% weight loss might be more than they seek, while for others, it could be the necessary amount to achieve improved health, suggesting that not all patients will require or tolerate the highest dose for extended periods.
This latest data represents the third set of late-stage results for retatrutide, following its success in a diabetes trial earlier this year and a smaller study on patients with obesity and knee arthritis in December. Eli Lilly is heavily investing in retatrutide as a foundational element of its obesity treatment portfolio, building upon the success of its blockbuster weight loss injection Zepbound and its recently introduced pill, Foundayo.
In a January note, TD Cowen analysts projected that retatrutide could generate sales of approximately $3.8 billion by the year 2030. The development and potential market entry of retatrutide are crucial for Eli Lilly's strategy to maintain its dominant market share over competitor Novo Nordisk in the rapidly expanding market for weight loss and diabetes drugs. Analysts estimate this market segment could reach a valuation of around $100 billion by the 2030s.
A notable aspect of the trial was the testing of a new, lower 4-milligram dose of retatrutide, which was not included in previous studies. This lower dose demonstrated efficacy, helping patients lose an average of 19% of their body weight, or approximately 47.2 pounds, over the 80-week study period. Skovronsky commented that the weight loss achieved with this lowest dose is comparable to that of Zepbound at its high doses, but importantly, it was accompanied by "a really excellent tolerability profile" that surpassed Lilly's expectations. This refers to the drug's manageability by patients, a critical factor for medications in the GLP-1 class, which are often associated with gastrointestinal side effects.
The discontinuation rate due to side effects for patients on the 4-milligram dose was lower than that of the placebo group, a finding Skovronsky described as "remarkable." Specifically, about 4% of patients on this low dose discontinued treatment because of side effects, compared to nearly 5% in the placebo group. This contrasts significantly with the 11.3% discontinuation rate observed among patients taking the highest dose of retatrutide.
"I think we're making history here, both on the high end with the high dose and on the low dose for what we can offer patients," Skovronsky remarked, highlighting the broad therapeutic potential of retatrutide.
Regarding safety, the data for Lilly's drug aligned with other GLP-1-containing medications, with the most frequently reported side effects being gastrointestinal in nature. Approximately 42% of patients on the highest dose experienced nausea, while around 32% reported diarrhea and 26.1% experienced constipation. Additionally, over 13% of patients on the highest dose reported an upper respiratory tract infection. More than 12% of patients at the highest dose also experienced dysesthesia, an abnormal nerve sensation previously noted in earlier trials.
Prior to the release of these results, some analysts had expressed concerns about potential cardiac issues, such as arrhythmia, associated with retatrutide, given its mechanism of action targeting three gut hormones, including glucagon, which influences energy expenditure. However, Eli Lilly reported no observed cardiac or liver issues. The company did note a slightly elevated rate of urinary tract infections (UTIs) in individuals taking the drug compared to the placebo group. Most of these UTIs were mild and resolved without patients discontinuing treatment. Skovronsky suggested that the increased incidence of UTIs might be linked to the rapid pace of weight loss, a phenomenon also observed following bariatric surgery.
Retatrutide, often referred to as the "triple G" drug, targets GLP-1, GIP, and glucagon hormones. This multi-hormonal approach appears to exert more potent effects on appetite regulation and satiety compared to existing treatments that target one or two hormones. For context, tirzepatide, the active ingredient in Zepbound, mimics GLP-1 and GIP, while Novo Nordisk's semaglutide, the active ingredient in Wegovy, mimics only GLP-1.
Eli Lilly currently holds a significant 60.1% share of the U.S. obesity and diabetes drug market, as indicated by an earnings presentation. In contrast, Novo Nordisk's market share in the same period was 39.4%. As retatrutide progresses toward market availability, Novo Nordisk is actively working to counter Lilly's advancements. In March 2025, Novo announced an agreement to acquire rights to an early-stage experimental drug from Chinese pharmaceutical company United Laboratories International for up to $2 billion. This newly acquired drug is considered a potential competitor to retatrutide, as it also employs a three-pronged strategy for weight loss and blood sugar regulation. However, Novo's treatment is in a much earlier phase of development, suggesting it will likely take several years before it becomes available to patients.
